Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BruVenG
NCT05650723Phase 2Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- May 2023
- Primary completion
- Mar 2027
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, venetoclax, obinutuzumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Weill Cornell Medicine. Started May 2023; status: active, not recruiting.
02
Drugs
zanubrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05650723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650723.